# DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

Source: https://onco.cc/trials/nct07059650/  
OnCo record `nct07059650` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DZD8586 in diffuse large b-cell lymphoma, run by Dizal Pharmaceuticals, now recruiting.

## Summary

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) is a phase 1/2 interventional study registered as NCT07059650 by Dizal Pharmaceuticals, with 150 participants planned, started 2025-08-19 and due to reach its primary completion in 2030-10. Interventions recorded: DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07059650
- Phase: 1/2
- Setting: A Phase Ib/II, Multicenter Study to Evaluate the Efficacy and Safety of DZD8586 Combination Therapy in Diffuse Large B-cell Lymphoma
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07059650: https://clinicaltrials.gov/study/NCT07059650

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [DZD8586](https://onco.cc/drugs/dzd8586/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/nct07059650.json